Mainz Biomed NV (NASDAQ:MYNZ) has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines to access a portfolio of mRNA biomarkers for future integration into ColoAlert,
Mainz Biomed NV (NASDAQ:MYNZ) has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines to access a portfolio of mRNA biomarkers for future integration into ColoAlert, a detection test for colorectal cancer (CRC).
美因茨比亚德NV纳斯达克(Sequoia Capital:MYNZ)与法国兴业银行(Socpra Sciences Santéet Humaines)签署了一项技术权利协议,将访问一系列生物标志物,用于未来整合到结直肠癌检测测试ColoAlert中。
免责声明:社区由Moomoo Technologies Inc.提供,仅用于教育目的。
更多信息
评论
登录发表评论